The HMG-CoA reductase inhibitor simvastatin inhibits IFN-γ induced MHC class II expression in human vascular endothelial cells

Swiss Medical Weekly

Volumn 131, Issue 3-4, 2001, Pages 41-46

  Kwak, B ^a   Mulhaupt, F ^a   Veillard, N ^a   Pelli, G ^a   Mach, F ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Human endothelial cells; Immunosuppression; MHC class II; Statins

Indexed keywords

GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MESSENGER RNA; RIBONUCLEASE; SIMVASTATIN; TRANSCRIPTION COACTIVATOR CIITA; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG MECHANISM; FLOW CYTOMETRY; GENE ACTIVATION; GENE EXPRESSION REGULATION; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; HUMAN CELL; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; POSTOPERATIVE COMPLICATION; PROMOTER REGION; RIBONUCLEASE PROTECTION ASSAY; VASCULAR ENDOTHELIUM;

EID: 0035102526     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Cardiac allograft vasculopathy: Current concepts, recent developments, and future directions
2. Simvastatin decreases accelerated graft vessel disease after heart transplantation in an animal model
3. Coronary artery disease in cardiac allografts: Association with arteriolar endothelial HLA-DR and ICAM-1 antigens
4. Regulation of MHC class II genes: Lessons from a disease
5. Complementation cloning of a MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome)
6. Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA
7. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of transactivator CIITA
8. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials
9. Statin trials and goals of cholesterol-lowering therapy after AMI
10. Current perspectives on statins
11. The evolving role of statins in the management of atherosclerosis
12. Effect of pravastatin on outcomes after cardiac transplantation
13. Simvastatin reduces graft vessel disease and mortality after heart transplantation
14. Statins do more than just lower cholesterol
15. Functional CD40 is expressed on human vascular endothelial cells, smooth muscle cells, and macrophage: Implication for CD40-CD40 ligand signaling in atherosclerosis
16. Activation of MHC Class II transactivator CIITA by interferon gamma requires cooperative interaction between Stat1 and USF-1
17. The alloreactive and self-restricted CD4+ T cell response directed against a single MHC class II/peptide combination
18. Regulation of the mevalonate pathway
19. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors
20. Effects of a competitive inhibitor (mevolin) of 3-hydroxy-3-methylglutaryl coenzyme A reductase on human and bovine endothelial cells, fibroblasts and smooth muscle cells in vivo
21. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin
22. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients
23. Statins (HMG-CoA reductase inhibitors) as a novel type of immunomodulator